RESULTS:
Screening of 506,540 donations (June 2012-May 2018) yielded 1299 reactives, 177 of which were DNA and antibody positive and 25 DNA positive only. During the same time, 23 unscreened RBC units collected in Connecticut and Massachusetts were involved in TTB cases, making the risk of transmitting the infection from an unscreened donation in these two states 15.6-times greater than from a Babesia-negative unit. B. microti screening in Connecticut and Massachusetts has been associated with a reduction in TTB cases; none reported from blood donors residing in Connecticut since 2016. The positive donor rate has also decreased in Connecticut from 0.67% in 2013 to 0.23% in 2017. Ongoing follow-up testing has shown that only 10% of antibody-positive donors serorevert within 1 year, while 94% of polymerase chain reacton-positive donors become negative within 12 months.
CONCLUSIONS: Blood donation screening for
B. microti in endemic areas effectively mitigates TTB risk. Screening should be considered for all areas demonstrating ongoing risk defined as clinical cases or positive blood donors including those associated with TTB cases. B abesia microti, the intraerythrocytic parasite responsible for most of the babesiosis cases in the United States, is endemic in the northeastern and upper midwestern United States. B. microti is naturally transmitted by Ioxodes scapularis (i.e., the deer tick or black-legged tick), which often carries multiple pathogens, and is the vector responsible for transmission of the agents of Lyme disease and human granulocytic anaplasmosis. [1] [2] [3] [4] [5] The number of Babesia-infected ticks is on the rise, as well as the number of reported cases of babesiosis, which became a notifiable disease in 2011. 6 The clinical manifestations of babesiosis are generally mild and nonspecific (flulike, general malaise), but the infection may occur without symptoms. In the elderly and in individuals who are immunocompromised or are asplenic, the disease can be severe and life threatening. 7 using an arrayed fluorescence immunoassay (AFIA) to detect antibody and real-time polymerase chain reaction (PCR) for detection of parasite DNA. 13 Here, we summarize 6 years of B. microti blood donation screening, focusing on changing rates of B. microti-positive donors detected over time and the impact of testing on blood safety. Some of the data summarized in this article also appeared in a previous publication.
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MATERIALS AND METHODS
Screening protocol
Blood samples were screened for B. microti antibody and DNA under an investigational product-release testing protocol sponsored by IMUGEN, Inc. from June 2012 to May 2018. All testing was performed at IMUGEN under a Food and Drug Administration (FDA)-approved investigational new drug (IND) application. The performance characteristics of the screening assays were previously described. 13, 14 Briefly, antibody testing was performed by AFIA with a cutoff of 1:128, and B. microti DNA was detected by PCR.
Residual samples from donations found to be PCR positive and antibody negative (window period [WP]) were also tested by western blot for IgM and IgG, AFIA at a lower titer (1:32) and by an enhanced-sensitivity PCR. The sensitivity of the screening PCR assay is 66 parasites/mL and for the enhanced-sensitivity PCR is 10 parasites/mL, both at the 95% lower limit of detection.
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Selection of testing areas and sample collection A 5-mL ethylenediaminetetraacetic acid tube was collected for testing. Plasma was used for AFIA and whole blood for PCR. Screening occurred in B. microti endemic areas and included Connecticut, Massachusetts, Minnesota, and Wisconsin. Between 2012 and 2014, donations selected for screening were collected in highly endemic counties, identified based on the number of babesiosis cases reported. 13 After 2014, testing was performed under a cost-recovery model and extended to accommodate hospital requests for tested RBC components.
Follow-up testing
Donations identified as reactive by either test were removed from the blood supply, and donors were indefinitely deferred and invited to participate in a follow-up study, all as required by the IND protocol. DNA-positive, antibody-negative donors (i.e., those in the WP) were requested to provide samples weekly in the early stage of infection and then at 6 to 8 weeks, until PCR reactivity resolved and seroconversion occurred. The time interval for antibody-positive donors, regardless of their PCR status, was at 6 to 8 weeks, and were followed until their first antibody-negative result occurred (titer <1:64). At each follow-up appointment, ethylenediaminetetraacetic acid samples were collected and tested by AFIA and PCR.
Voluntary participants were released from the study after the first antibody-negative result.
Confirmatory criteria
As previously reported during the first 2-plus years of study, all donors whose initial reactivity repeated by a second test (AFIA, western blot, or screening, or enhanced PCR) at index or follow-up were considered confirmed positive. 13 However, based on reported specificity of the combination of tests used (>99.999%), 13 beyond this time, further supplemental testing was not deemed necessary for antibodyonly-positive donors if they were not enrolled in follow-up. Thus, all reactives were considered as positive and included for further analysis.
Mapping and statistical analysis
Survival estimates to determine the time to the first PCRnegative and antibody-negative results were prepared using a Kaplan-Meier model with the use of statistical analysis software (SAS version 9.4, SAS Institute). Maps reporting the zip code of residence of positive donors were prepared using mapping software (Mapland Spreadsheet Mapping for Microsoft Office 2013). Odds ratios were calculated; p values were calculated by Fisher's exact test.
Human subject approval
The study protocol and all study materials were approved by the American Red Cross Institutional Review Board.
RESULTS
Summary of testing
In collaboration with IMUGEN, the American Red Cross screened 506,540 donations from Connecticut (n = 287,721), Massachusetts (n = 98,898), Minnesota, and Wisconsin (n = 119,921) for B. microti between June 2012 and May 2018 (Table 1) . A total of 1299 donations were found positive, 177 of which were DNA and antibody positive and 25 DNA positive and antibody negative (WP). During the same time, an additional 1,163,607 donations were collected in Connecticut and Massachusetts by the Red Cross but not screened for Babesia. None of the donations tested for Babesia were involved in TTB cases, while 23 donations from the unscreened RBC donations resulted in TTB cases (Table 2) , making the odds of transmitting the infection from an unscreened donation in these two states 15.62 times more likely (p = 0.0026) than from a screened donation. 
Geographic distribution of positives (maps)
The highest number of positive donations was detected in Connecticut (n = 958), with a rate of 1:300, followed by Massachusetts, with 1:469 reactive donations (n = 211), and the North Central region, including Minnesota and Wisconsin, with a combined positive rate of 1:1187 positive donations (n = 101) (Fig. 1) . Most (83%) positive samples were antibody positive only, but DNA-positive samples (including WP donations) were detected in all four states, indicating active transmission. The maps do not include 29 positive donations collected in one of the four regions but were donors residing in other states.
Follow-up samples (survival curves)
Follow-up participation rate was 57% (749 of 1,299), with 529 participants providing two or more samples and 220 donors providing one follow-up sample. Only donors who provided two or more follow-up samples were included in the analysis. A Kaplan-Meier estimated analysis of the duration of DNA and antibody in positive donors shows that 94% of DNA-positive donors became PCR negative within 1 year (with 50% of those who were AFIA positive resolving by 2.3 months and 50% of those who were AFIA negative resolving by 4.6 months) ( Fig. 2A ). In contrast, antibodies were no longer detectable in only 10% of antibody-positive donors regardless of their PCR status after 12 months (Fig. 2B and C) . In Fig. 2B , the 18 antibodynegative index donations (<1:128) were from WP donors. We had only one donor with an index donation that was PCR positive and antibody positive with a titer of 1:128 (thus excluded from Fig. 2C ).
Increase of testing and decrease of TTB cases
Testing has expanded over time in Connecticut and Massachusetts. Respectively, 96% and 27% of the donations of whole blood and RBCs were tested for B. microti in these states in 2017 (Fig. 3) . In the same year, no cases of TTB were reported from blood donors residing in these two states. This is a noticeable reduction from previous years, when the combined number of TTB case reported from Connecticut and Massachusetts donors each year varied from four to nine.
Reduction of positive donations over time in Connecticut
The number and frequency of positive donations detected during B. microti testing has gradually decreased over time in Connecticut, where screening has been extensive (Fig. 4) The decrease in the number of positive donations detected in Connecticut and the persistence of the antibody long after the infection has been cleared could be connected in that the systematic deferral of antibody-only-positive donors, who represent most of the donations identified as positive, gradually reduced the number of donors with "old infections" and long-lasting antibody from the pool of eligible donors. As a result, where screening is close to 100%, positive donors should mostly be represented by new infections or donors tested for the first time. In support of this hypothesis, the percentage of Connecticut first-time donors who were positive for B. microti in 2017 was almost double the previous year, suggesting that more positive donations were detected from donors who were never tested before (data not shown). Additionally, as compared to our previously published 2010 results, the overall frequency of Babesia positivity has decreased in all areas in which testing has occurred, again likely due to the deferral of prevalent positive donors (i.e., 0.33% in Connecticut, 0.21% in Massachusetts, and 0.084% in Minnesota/Wisconsin). 14 An unusually high number of WP donors were detected in the summer of 2017, in line with predictions of a particularly high tick season. Monitoring of environmental factors such as mild winters and large acorn crops can help predict the intensity of the tick season 2 years in advance. 16 In fact, a connection has been suggested between periodically large acorn crops and a large population of mice. As a result, hatching tick larvae feeding on infected mice the following summer will have a greater chance of survival and pathogen infection that could affect the human incidence of tick-borne diseases. On March 6, 2017, IMUGEN received FDA licensure for both tests (antibody and PCR). Subsequently, in July 2018, the FDA released a draft guidance with a recommendation for reducing the risk of TTB by using both licensed tests. However, this testing option is no longer available, as IMUGEN has discontinued B. microti blood donation screening. B. microti screening continues at the Red Cross under a different IND protocol, using a nucleic acid test (NAT) targeting ribosomal RNA versus a single parasite DNA template for the real-time PCR. This approach is expected to increase analytic sensitivity (1.4 parasites/mL vs 66 parasites/mL, respectively, at the 95% lower limit of detection). 17 Alternatively, pathogen inactivation has been shown to be effective in reducing B. microti in a variety of components. 18, 19 RNA-positive donation identified by universal Zika virus screening, the cost of B. microti screening is quite modest. 21 Blood donation screening in Connecticut and Massachusetts has been associated with a significant reduction in TTB cases, demonstrating that testing in endemic areas is a successful strategy. However, while the infectious status of donors with positive NAT results is undeniable, the need to defer donors with antibody-only-positive results remains arguable, especially with the availability of more sensitive NAT assays. NAT (as assessed by the detection of DNA or RNA) is the direct marker of infectivity versus antibody, which serves as a surrogate assuming that direct assays may lack the needed clinical sensitivity, an assumption that should be challenged. Ultimately, the goal of blood donation screening for B. microti (or other human Babesia species capable of transfusion transmission) is to prevent transfusion of infectious blood components. Thus, screening using the appropriately validated tests should be considered in areas demonstrating ongoing risk due to clinical cases and positive blood donors, including those associated with TTB cases. 
